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Abstract 
Previous attempts to determine the structure of the protein PhoH2 from 
Mycobacterium tuberculosis, Mycobacterium smegmatis and Thermobispora 
bispora have been unsuccessful producing diffraction data to low resolution. The 
thermophilic organism Caldalkalibacillus thermarum was thought to be an 
advantageous option from which to clone, express and purify PhoH2 from for the 
purpose of structure determination. PhoH2 consists of two domains, an 
N terminal PIN domain, known for its toxic properties as part of many toxin-
antitoxin systems present in M. tuberculosis, and a C-terminal PhoH domain, an 
RNA helicase suspected to be involved in phosphate starvation responses. The 
cloning and expression of three variations of recombinant C. thermarum PhoH2 
was successful in Escherichia coli. However the purification of PhoH2 continues to 
yield insoluble protein, despite the range of purification buffer conditions 
screened, thus preventing downstream biochemical characterisation and 
structural investigations. Multiple options exist to overcome this insolubility 
problem; including alternate plasmids for protein expression and purification that 
alter the tag location and type such as C-terminal His-tags and alternative fusion 
tags. 
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1 Introduction 
1.1 Tuberculosis 
The disease tuberculosis (TB) remains globally the second highest cause of death 
by a single infectious agent (caused by Mycobacterium tuberculosis) ranking 
behind the human immunodeficiency virus (HIV) [2]. Despite the availability of the 
preventative Bacille Calmette-Guérin (BCG) vaccine and known therapy options 
including strict 6 month antibiotic treatments with rifampicin and isoniazid [3], the 
prevalence of TB worldwide is high particularly in developing countries. According 
to the Global tuberculosis report 2015, 9.6 million people worldwide are 
estimated to have fallen ill with the disease, with 1.5 million of those cases being 
fatal [2]. Increased risk to exposure and infection of TB occurs in Africa and South-
East Asia and the Western Pacific, with these regions accounting for 21.5%, 40.95 
% and 22.1% respectively, and are now considered to be on the TB burden country 
list (Figure 1.1) [2].Contributing factors to increased risk of TB burden include 
poverty, immuno-depressive drugs and infection by HIV [4]. Although it has long 
been thought human TB disease originated from the Bovine TB disease, genetic 
research into the two closely related strains suggests this may not be the case, and 
human TB, as a result of the 
bacterium M. tuberculosis, is 
likely to be closest to the 
ancestral bacilli [5]. 
Pulmonary TB; infection of 
the lungs, is the most 
common form of TB, 
however extra-pulmonary 
infections have been 
observed in peripheral areas 
of the body. TB disease progresses following human inhalation of tuberculosis 
bacilli in aerosol droplets into the lungs where the Mycobacteria proliferate inside 
macrophages in the alveolar space, rather than being destroyed by the immune 
Figure 1.1: Global estimated TB incident rates 
according to population. Figure taken from WHO 
(2015) [2]. 
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response[4, 6]. This triggers the attraction of other immune cells which form a 
granuloma known as the hallmark of TB [7]. The granulomas create a 
microenvironment with extreme conditions such as nutrient starvation, low pH 
and hypoxia [8]. 
The Mycobacteriaceae family of bacteria which are genus of Actinobacteria are 
responsible for a wide range of often fatal diseases in mammals. In addition to TB, 
Leprosy (Hansen's disease) is also a mycobacterial disease which is less prevalent. 
Mycobacterial diseases such as TB are difficult to treat and to do so, require long 
courses combining multiple antibiotics [3]. Extensively Drug Resistant (XDR) strains 
are becoming increasingly prevalent, where antibiotic resistance is occurring[9]. 
Antibiotic resistance is increasing at an alarming rate across many diseases caused 
by a range of bacteria, including pneumonia, gonorrhoea and tuberculosis [10]. 
Although resistance occurs naturally, the over-prescription of antibiotics and over-
the-counter supply of antibiotic treatments are exacerbating the issue [11]. The 
World Health Organisation (WHO) issued a report indicating a full review of how 
and when antibiotics should be prescribed to treat infections and diseases as a 
way to slow the progression of antibiotic resistance, specifically for TB [10].  
A defining feature of Mycobacteria is their unique cell wall structure, thought to 
be crucial to the strength and resistance of this bacterial family [12].This acts as a 
barrier to permeation and therefore prevents molecules, including drugs from 
entering the cell [12].  This unique strength of the cell wall is often a limiting factor 
to many of the studies which attempt to understand more about this class of 
bacteria. 
Dormant M. tuberculosis must be able to survive the toxic conditions in the 
granuloma for extended periods of time [13]. In addition to the unique cell wall, 
M. tuberculosis has reduced metabolism and replication, the details of which are 
still poorly understood [14]. There are multiple suggestions as to the changes 
M. tuberculosis undergoes to survive under such conditions over the long term 
within the granuloma. For example, transcriptional profiling of M. Tuberculosis 
shows that the genes encoding sulphur metabolism are regulated by 
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environmental cues, such as that of nutrient starvation and decrease in oxygen 
and carbon dioxide levels [15]. Control of the hosts apoptosis response by 
adaptation of metabolism has been reviewed in detail [16]. Increased production 
of Interleukin-10 (also known as human cytokine synthesis inhibitory factor) 
bound to TNFR2 (Tumor Necrosis Factor Receptor 2) by the Mycobacterium in 
response to the hosts increasing T cell immune response, results in the 
Mycobacterium halting the apoptosis cycle and increasing the viability of the 
infecting organism [17]. 
A key genomic feature that has been linked to dormancy and long term survival 
(in addition to the physical features of the Mycobacterial cell wall), is the unusually 
large number of toxin-antitoxin genes encoded in the M. tuberculosis genome, a 
total of 79 at last count (Figure 1.3) [18, 19]. 
1.2 Toxin-Antitoxin Systems 
A toxin-antitoxin (TA) system is two closely spaced genes, often as part of an 
operon. The first TA system was discovered on a plasmid and had a role in 
maintaining the plasmid in bacterial daughter cells [19]. These genes encode for a 
specific protein toxin which evokes a highly toxic effect on the cell, such as cell 
death or growth arrest. A second unstable antagonistic antitoxin, which can be 
either a protein or non-coding RNA, is also expressed which is able to neutralise 
the toxin under strict optimum conditions [20], [1]. 
Toxin-antitoxin systems have been classified into 5 distinct groups, according to 
their antitoxin mechanism of inhibition (Figure 1.2) [21, 22].  
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Figure 1.2: Mode of action of the five classified toxin antitoxin systems. Figure 
taken from Wen, Behiels & Devreese (2014)[22]. 
 Type I - non-coding sRNA inhibits the translation of the toxin mRNA by 
degrading or blocking the ribosome binding site.  
 Type II - both toxin and antitoxin are small peptides, in which the binding 
of the antitoxin to the toxin causes neutralisation of the toxin (Figure 1.4).  
 Type III - toxins are proteins which are inhibited by RNA antitoxin 
pseudoknots.  
 Type IV - TA systems have protein components for both the toxin and the 
antitoxin. Inhibition of the toxin occurs when the antitoxin stabilises the 
target proteins, thereby blocking the toxin.  
 The final group of TA systems has only recently been discovered, Type V 
systems have a protein antitoxin which binds and degrades the mRNA of 
the toxin [23]. 
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Type I and Type II TA systems are of particular interest to the field of Mycobacteria 
research, such as M. tuberculosis and M. Leprae [23, 24]. In the M. tuberculosis 
genome H37Rv, there are 77 TA systems known, 68 are Type II TA systems of which 
50 are Virulence Associated Protein (VapBC) TA systems [19]. 
 
Figure 1.3: The toxin-antitoxin genes present in the M. tuberculosis genome. Dark 
blue TA systems have been identified as most commonly induced in drug-tolerant 
cells. Red dots indicate inhibition of growth, while grey indicates no growth 
inhibition in E. coli, M. smegmatis and M. Tuberculosis. Figure taken from Sala, 
Bordes & Genevaux (2014)  [19]. 
Type I toxins are small hydrophobic peptides ranging between 20-65 amino acids 
in length[1, 20]. These act by disrupting the membrane potential of invading cells 
[25]. Type I antitoxins are small non-coding antisense RNAs which inhibit the toxin 
either by blocking the ribosome binding site, or degrading the toxin’s mRNA [23]. 
Multiple Type I TA systems have been discovered in both Gram-positive and Gram-
negative bacteria and archaea [26]. The transcription of the toxin gene is regulated 
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by the antisense RNA antitoxin, which covers the toxin gene, but is in the reverse 
direction (Figure 1.4) [1, 24]. The antisense RNA antitoxin of type I TA systems, 
such as the Hok-Sok, SymR-SymE and IstR-TisB TA systems, when transcribed, 
binds to the toxin mRNA which forms a double stranded RNA molecule [1]. It is 
believed that this formation of the double stranded RNA molecule targets it for 
degradation by exoribonucleases, thereby inhibiting the expression of the toxic 
protein [24]. The most understood of Type I TA systems is the Hok-Sok system, the 
first TA system to be discovered in 1986 in Escherichia coli. Studies of the Hok-Sok 
system along with other type I TA systems predominantly in E.coli have identified 
a conserved secondary structure to the toxin protein with a single α-helical 
structure thought to be crucial to the mechanism of toxicity; disruption of the 
cellular membrane potential [1, 19, 26]. 
Type II TA systems differ from Type I TA systems as both components of the Type 
II systems are proteins (Figure 1.4) [19, 25]. Like the Type I TA systems, the gene 
encoding the antitoxin component is upstream of the toxin gene, but in Type II 
systems is in the same 5' to 3' orientation as the toxin gene [1]. Typically, the toxin 
proteins are larger than the Type I toxins, with protein sequences ranging between 
40-206 amino acids in length [27].The antitoxin protein binds to the toxin protein 
(Figure 1.4), and either blocks the active site of the toxin, or induces steric changes 
to the toxin, resulting in a non-functional protein, unable to exert its toxicity on 
the cell [19]. 
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Type II TA systems which have been identified and characterised include 5 families 
of toxin Proteins; MazEF, RelBE, ParDE, YefM/YoeB, HigB, TAC and VapBC. 
In M. tuberculosis these TA systems have been identified as occurring in the 
genome 10, 2, 2, 1, 2, 1 and 45+ times respectively. In contrast to other bacteria 
where very few (1-5) TA operons are observed, this uniquely high VapBC TA 
operon presence has prompted multiple studies into the purpose of TA systems, 
and the possible implications these have in relation to the unique characteristics 
of this pathogenic mycobacteria [28]. 
Although specific roles of the VapBC TA systems in general are still not fully 
understood, there recently has been some evidence that these are involved in 
Figure 1.4: A schematic diagram of the (a) Type I and (b) Type II toxin 
antitoxin systems. Of particular importance is the direction of the antitoxin 
gene [1]. 
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regulating cellular processes, particularly in Mycobacteria[24]. These include 
cellular processes such as bacterial growth, stabilisation of genomic regions, 
defence against invading pathogens, nitrogen fixation, biomass production, 
induction and control of stress response, and bacterial persistence [29]. In E. coli, 
by inducing a range of Type II TA systems it was observed that bacterial persistence 
was significantly increased, thus indicating a major role of TA systems [19]. It is 
speculated that understanding and possibly exploiting these TA systems in 
M. tuberculosis may lead to the development of effective and efficient treatment 
options. 
 
1.2.1 PIN Domains 
The VapBC TA systems are defined by their toxin (VapC) component containing a 
PilT-N terminus (PIN) domain [30]. PIN domains are small proteins of 
approximately 130 amino acids long. These PIN domains have since been 
discovered in bacteria, archaea and eukaryotes which has generated the thought 
that these domains have roles in cellular maintenance [31]. While the amino acid 
sequence for the PIN domain family has very low identity, four amino acids are 
strictly conserved and form the enzymatic active site of the three-dimensional 
structure (Asp, Glu, Asp, Asp) (Figure 1.5)[32, 33]. Approximately 95% of PIN 
domains exist as single domain proteins, while the remaining 5% are fused with 
AAA+ ATPase domains, TRAM and KH domains [34]. 
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Figure 1.5: Hidden Markov Model (HMM) of PIN domain proteins. Of importance 
is the four conserved residues D, E, D, D that are conserved at strict positions as 
indicated by the height and width of each letter. Generated from pFam, [35]. 
Structurally, PIN domains have been characterised with alpha-beta-alpha (αβα) 
sandwich topology, with the conserved amino acid residues composing the active 
site responsible for exerting the toxic effect (Figure 1.6) [36]. While the four 
conserved amino acids vary in sequence distance, spatially they are positioned 
closely to enable the binding of Mg2+ ions and form the active site of the toxin 
nuclease (Figure 1.6) [31]. To date, all characterised PIN domain toxins are active 
as dimers. This dimerisation occurs along the long-axis of the PIN structure, 
positioning the active sites in a groove, enabling their toxic effect [32]. 
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Figure 1.6: The structure of PIN domains found in 
PyrobaculumaerophilumPAE2754. Figures were made with Pymol 
(http://www.pymol.org/) using PDB 2FEI [31, 32]. 
PIN domain toxins are RNAses that target RNA by specific mechanisms, with 
varying PIN domain proteins targeting tRNA, rRNA or mRNA transcripts [19, 29]. 
The M. tuberculosis genome has a rich GC content of 66%, thus the observation 
that PIN domain toxins target and cleave GC rich regions in mRNA is no surprise 
[19]. How the PIN domain toxins specifically recognise their cleavage targets 
remains enigmatic, however a few studies have identified a stable hairpin motif 
which creates double stranded RNA (Figure 1.7) [29]. A consensus sequence in M. 
smegmatis has been identified following sequencing where up-stream of the 
hairpin loop is AUA(A/G) and other conserved nucleotides [37]. 
An identified rRNA targeting PIN domain toxin, VapBC20, specifically cleaves the 
Sarcin-Ricin loop. This inhibits translation as the Sarcin-Ricin loop is crucial for the 
assembly of the functional group of the 50S ribosomal subunit [38].  
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Figure 1.7: Schematic diagram outlining the conserved nature of the nucleotides in 
the hairpin structure in PIN domain toxin RNA substrates (figure taken from 
McKenzie, Robson [29]). 
While no definitive studies into the characteristics of the type II antitoxins have 
been conducted to date, there are a few observations. An extensive search and 
analysis of the TBDB (Tuberculosis Data Base) revealed that the 50 VapBC 
antitoxins in M. tuberculosis, are generally half the length of the toxin protein that 
it inhibits, with lengths varying between 40% to 60% of the toxin component. 
Other features of antitoxins appear to be the presence of an arginine (R) amino 
acid residue in the last approximately 5 residues. In many structures of TA 
complexes, this positively charged side chain interacts with the negative side 
chains of the conserved residues forming the active site of PIN domain proteins 
[28]. 
1.3 Helicase  Proteins 
In order for the PIN domains to be able to execute their toxicity on their associated 
targets, the RNA sequence must be exposed, typically this is conducted by helicase 
proteins. Helicase proteins target either DNA or RNA and unwind the helices in 
order to expose the strands. Helicase enzymes require the hydrolysis of ATP for 
energy to unwind the strands. The helicase superfamily I has long been known to 
be comprised of 2 independent domains linked together by a non-conserved 
flexible linker region [39]. The N-terminal domain, and the YjhR C-terminal domain 
[39]. 
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1.3.1 PhoH Domains 
Very little is known about PhoH domain proteins with literature searches showing 
less than 5 publications. Bioinformatic investigations of PhoH proteins from E.coli 
and Corynebacterium glutamicum have identified similarities to helicase 
superfamily 1/2 proteins [39]. PhoH contains some of the conserved motifs in 
superfamily 1 helicase proteins of the N-terminal domain, but lacks the motifs 
found in the C-terminal domain (Figure 1.8). One such conserved motif is the 
Walker B of DNA and RNA helicases, also known as the DEAD box due to the 
residues present. This motif is characteristic of all ATPases and helicase proteins 
and is involved in the turnover of ATP [40]. The helicase motifs in the N-terminal 
domain of Superfamily I are required for ATP binding and hydrolysis, and 
intramolecular rearrangements [39]. It was identified that PhoH also appears to 
have 2 sequence motifs unique to PhoH; an arginine residue and a conserved 
sequence RGRTL, these have been experimentally verified to be involved with RNA 
recognition and binding(Figure 1.8)[34].The other conserved motifs found in PhoH 
are identified across proteins belonging to all 6 of the helicase families [34]. 
 
Figure 1.8: Hidden Markov model (HMM) of PhoH proteins. Conserved motifs are 
annotated as described in [32]. Generated from Pfam [35]. 
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Like superfamily 1 helicase proteins, PhoH from C. glutamicum, the only PhoH 
structure in the PDB, shows a strong beta strand topology[41]. 
Because of these similarities, PhoH is likely to have helicase activity. It was 
reported when PhoH is found fused to a PIN domain protein to have unwinding 
activity (See 1.4 PhoH2 fusion protein) [34]. It has been speculated that PhoH 
proteins have a role during conditions of phosphate starvation [42]. In E. coli 
phosphate starvation induces a change in metabolism and gene expression to 
adapt to the conditions. This has been observed as a trigger of bacterial virulence 
in Mycobacteria, although the details are still not well known[43, 44]. 
 
1.4 PhoH2 fusion protein 
PhoH2 proteins, the protein family of interest in this study, is a fusion between a 
PIN domain (VapC) at its N-terminus and a PhoH domain at its C-terminus. These 
are linked together by a long flexible linker region that does not correspond to any 
known conserved domains (Figure 1.9). 
 
 
PhoH2 from Mycobacteria has been biochemically characterised as an ATP-
dependent RNA helicase and degradation protein specifically targeting RNA 
sequences with the 5' sequence AC[A/U][A/U][G/C] in the presence of ATP. The 
two unique motifs identified in PhoH not observed in any of the other 6 helicase 
families were found to be essential for unwinding activity [34]. In Mycobacteria, it 
was found that PhoH2 is posing as a variation of a type II TA system in which a 
small protein antitoxin is located upstream and overlapping the start of the PhoH2 
PhoH Domain PIN Domain 
Flexible Linker Region 
PhoH2 Figure 1.2: Schematic arrangement of the PIN and PhoH domains in PhoH2 from C. 
thermarum. 
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gene. This small antitoxin was required to gain soluble protein expression of 
PhoH2 from M. tuberculosis but was not required to gain soluble PhoH2 protein 
from M. smegmatis. The presence of antitoxins upstream of the PhoH2 gene is 
limited to Mycobacteria as none have been identified in other organisms to date. 
This short antitoxin when expressed with PhoH2 from M. tuberculosis prevents an 
otherwise toxic effect that PhoH2 expression has on the growth of M. 
smegmatis[34]. 
Extensive efforts in the Proteins and Microbes lab (University of Waikato) have 
been unsuccessful in producing structural data to a high resolution using PhoH2 
proteins from M. tuberculosis, M. smegmatis or Thermobispora bispora. While 
modest resolution has been achieved with a mutant of T. bispora, the 
3-dimensional structure and therefore, insights into the functioning of PhoH2 
proteins and how an RNase fused with an RNA helicase is coordinated, remains 
enigmatic. 
1.5 Caldalkalibacillus thermarum 
The genome of Caldalkalibacillius thermarum (C. thermarum) TA2.A1 has been 
sequenced (GenBank: AFCE00000000.1) [45] and a homologue of PhoH2 was 
identified using BLAST with a 39 % sequence similarity to PhoH2 from M. 
tuberculosis and T. bispora. 
C. thermarum TA2.A1 is a thermophilic alkaphile, found to be growing in hot 
springs around the world, and locally in Te Aroha, Waikato, New Zealand [46]. This 
environment has extreme conditions and as such C. thermarum TA2.A1 grows 
optimally at 65 °C and at pH 9.5 [46, 47]. PhoH2 from C. thermarum is particularly 
attractive as a research target due to its lack of corresponding antitoxin suggesting 
a lesser toxic effect on cell growth than typically found with other PIN domain 
operons. The lack of antitoxin protein has been defined by the absence of an 
arginine residue in the approximately last 5 residues prior to the beginning of the 
PIN domain and the absence of start sites in frame with a stop codon overlapping 
the start of the PhoH2 gene. Secondly, other research labs have had success in 
studying large and difficult proteins to solve structures and other biochemical 
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attributes from C. thermarum. A recent example of this is the study of ATP 
synthase conducted by a research group at the University of Otago in 2005 [48]. 
Prior to studying the ATP synthase from C. thermarum, the structural 
investigations into this protein from E.coli and Bacillus sp. PS3 had failed in 
providing structural features key to the biochemical function of the enzyme [48]. 
Following solving the structure of ATP synthase from C. thermarum, this research 
group has gone onto using molecular modelling to solve the structure of similar 
ATP synthase enzymes from other organisms [49].Thirdly, C. thermarum poses as 
an alternate thermophile to T.  bispora that led to moderate success in 
crystallographic studies. Therefore, C. thermarum poses as an attractive candidate 
for further structural studies of PhoH2. 
1.6 Objectives 
The overall aim of the following research is to determine the structure and three-
dimensional characteristics of the novel protein PhoH2 from C. thermarum. The 
characterisation of PhoH2 was carried out in terms of the following objectives. 
 Clone, express and purify PhoH2 protein from C. thermarum. 
 Conduct biochemical assays to characterise the activity of PhoH2 from 
C. thermarum. 
 Using purified protein, grow diffraction quality crystals of PhoH2.  
 Solve the structure of PhoH2 from C. Thermarum by X-ray crystallography. 
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2 Materials and Methods 
2.1 DNA Manipulations 
2.1.1 Genomic DNA extraction 
2.1.1.1 Media and Growth Conditions 
Caldalkalibacillus thermarum TA2.A1 was grown routinely in TA2.A1 classic media 
containing 2.5 mL of 200x Dictyoglomus trace elements (2.8 mg ZnSO4, 0.38 g 
MgCl2.6H2O, 0.05 g CaCl2, 0.039 g Fe(NH4)2(SO4).6H2O, 1 g Na2CO3, 2.9 mg 
CoCl2.6H2O, 2.4 mg NaMoO4.2H2O, 0.17 mg Na2SeO3 and 2.0 mg MnCl2.4H2O, pH 
9.5) at 65 °C with agitation at 200 rpm. 
E. coli strains were grown in Luria broth (LB); 1 % peptone, 0.5 % yeast, 0.5 % NaCl) 
at 37 °C with agitation at 200 rpm, and supplemented with appropriate antibiotic, 
Kanamycin 50 mg/mL. 
2.1.2 Vector DNA extraction from E coli 
A Qiagen Plasmid extraction kit was used to extract DNA from E. coli cells following 
growth overnight at 37 °C in LB medium. 
2.1.3 Agarose Gel Electrophoresis 
One % Agarose Gel electrophoresis was used to separate DNA fragments. A 1 kb 
PLUS DNA Ladder was included to provide a standard of DNA band sizes 
(Invitrogen, USA). Samples were mixed with 10x DNA loading dye (50 % glycerol, 
0.4 % bromophenol blue) prior to loading. Gels were prepared using 1x SYBRSafe™ 
DNA gel stain (Invitrogen, USA), and run in 1x TAE buffer (40 mM Tris acetate, 
2 mM EDTA) at 100 V for 40 minutes. Gels were visualised using a blue light box 
(Invitrogen, USA) and images captured. 
2.1.4 DNA Quantification 
Quantification of DNA was done using a Nanodrop ND-1000 Spectrophotometer 
(Nanodrop Technologies, USA). The Nanodrop quantifies DNA by measuring 
absorbance of DNA at 260 nm, and the purity of samples determined by the 
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260/280 and 260/230 ratios indicating respective protein and carbon 
contamination. 
2.1.5 PCR 
PCR reaction temperatures were optimised by a gradient of temperatures 
between 5 °C above and below the primers calculated Tm. 
2.1.5.1 Primers 
All primers were a minimum size of 20 bp in length, with primers used for ligase-
based  cloning containing flanking restriction enzyme sites with an additional 2-4 
bases to increase efficient cleavage. All primers were supplied by IDT (USA) and 
dissolved to a 100 µM concentration in 1x TE buffer, then further into a working 
concentration of 10 µM. 
2.1.5.2 PCR for amplification of PhoH2 from Genomic DNA for Vector inserts 
Table 2.1and Table 2.2 describe the PCR amplification methods and cycling 
parameters used in this study. 
Hot FirePol DNA 
Polymerase 
KAPA HiFi™ HotStart Taq Polymerase 
1 x Buffer B1 1x KAPA 5x HIFI GC 
Buffer 
1x PCR buffer 
0.05 U HOT FIRE pol 1 U KAPA HiFi Hotstart 
DNA Polymerase 
2.5 U Taq DNA 
Polymerase 
2.5 mM MgCl2 10 mM KAPA dNTP Mix 1.5 mM MgCl2 
200 µM dNTP Mix  0.3 µM Each Primer 0.2 mM dNTP Mix 
0.3 µM Each Primer 1-10 ng DNA template 0.5 µM Each Primer 
1-10 ng DNA template  20-120 ng DNA Template 
Table 2.1: PCR reactions used in the following study. Hotfire pol used for cloning. 
KAPA HiFi Hotstart used when cloning has been difficult. Taq Polymerase, a non-
proofreading Polymerase used for screening colonies. 
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Hot FirePol DNA 
Polymerase 
KAPA HiFi™ HotStart Taq Polymerase 
Cycling conditions (min:sec) x 29 cycles 
95 °C 15:00 (initial 
denaturation) 
95 °C 2:00 (initial 
denaturation) 
95 °C 2:00 (initial 
denaturation) 
95 °C 0:20 98 °C 0:20 95 °C 0:15 
Tm * 0:30 Tm * 0:15 Tm * 0:30 
72 °C 1:00** 72 °C 0:45** 72 °C 0:45** 
72 °C 5:00 (final 
extension) 
72 °C 5:00 (final 
extension) 
72 °C 5:00 (final 
extension) 
Table 2.2:  Cycling conditions for each of the PCR reactions used. 
*Tm determined by gradient PCR 
**Elongation time dependent on length of insert 
 
 Primer Sequence 
C. thermarum PhoH2 
Cloning Forward 
TTGAAAAAAATATATGTTCTGGATACCAATGTTCT 
C. thermarum PhoH2 
Cloning Reverse 
GTTCCCCTCTGGCCCAACTTGCTGCCCACGTTCTT 
C. thermarum PhoH2 
PstI  Forward 
AAAACTGCAGATGAAAAAAATATATGTTCTGGAT 
C. thermarum PhoH2 
XbaI Forward 
CTAGTCTAGAATGAAAAAAATATATGTTCTGGAT 
C. thermarum PhoH2 
HindIII Reverse 
CCCAAGCTTAAGAACGTGGGCAGCAAGTTGGGC 
C. thermarum PhoH2 
HindIII Reverse with 
Native Stop 
CCCAAGCTTTTAAAGAACGTGGGCAGCAAGTTGGGC 
pET28b-Htb Sequencing 
4877 Forward 
CATCGGTGATGTCGGCGATA 
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T7 Forward TAATACGACTCACTTTAGGG 
T7 Reverse GCTAGTTATTGCTCAGCGG 
pET28b-Htb Insert a 
Forward 
TTAAGAAGGAGATATACTGCAGATGAAAAAAATAT 
pET28b-Htb Insert b 
Forward 
TAATTTTGTTTAACTTTAAGAAGGAGATAT 
pET28b-Htb Insert c 
Forward 
CTAGTCTAGAAATAATTTTGTTTAACT 
pPROEX-Htb 30 EcoRI 
Forward 
CGGAATTCAAATGAGTCATACACATAAAAATAAAA 
pPROEX-Htb 18 EcoRI 
Forward 
CCGGAATTCAAATGTATATTTTTCCAAGGCCAGTT 
pET28b-Htb-pstI 30 
EcoRI Forward 
CGGAATTCATGAGTCATACACATAAAAATAAAACA 
pET28b-Htb-pstI 18 
EcoRI Forward 
CGGAATTCATGTATATTTTTCCAAGGCCAGTTGAT 
Table 2.3: Primers designed for cloning and sequencing C. thermarum PhoH2, 
ordered from IDT technologies. 
2.1.6 Purification of PCR product in solution 
A commercial High Pure PCR Product Purification Kit (Roche Applied Science, 
Switzerland) was used to purify PCR or enzymatic reaction products following 
pooling of 15 µL reactions. 
2.1.7 Restriction Enzyme Digest 
Restriction enzyme digests were performed by the Cutsmart double digest system 
following the manufacturer's instructions. Buffers used were chosen as 
recommended by the manufacturer to maximise the efficiency of the DNA digest. 
Incubations were carried out at 37 °C for three hours. Restriction enzymes were 
purchased from Invitrogen (USA). Double digestions were used when the reaction 
buffers were compatible for both enzymes. Following incubation, reactions were 
purified according to the method in section 2.1.6.  
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2.1.8 DNA Ligation 
DNA Ligation reactions were conducted following the manufacturer's 
recommendations. One uL of T4 DNA Ligase (Invitrogen, USA), 1x Ligase buffer and 
a 1:3 ratio of insert:vector, and MilliQ H2O to a final volume of 20 µl. DNA Ligase 
reactions were incubated at 18 °C overnight. 
2.1.9 DNA Transformation 
2.1.9.1 Preparation and transformation of chemically competent E. coli. 
The following method was used for the preparation and transformation of both 
DH5α and BL21 chemically competent E. coli strains. 
A single colony of DH5α or BL21 cells was cultured overnight in 10 mL of LB media 
at 37 °C, 200 rpm. One mL of this starter culture was used to inoculate 100 mL of 
LB at 37 °C at 200 rpm until OD600= 0.5-0.7 was reached. The 100 mL culture was 
then split into 2x 50 mL and chilled on ice for 30 minutes followed by 
centrifugation at 4000x g for 10 minutes at 4 °C.  The cell pellet was then 
resuspended in 10 % of the original culture volume of ice cold TSB media. Aliquots 
of 100 µL were then snap frozen in liquid nitrogen and stored at -80 °C.  
Aliquots of chemically competent cells were thawed on ice and 1-10 µL of the 
desired plasmid or ligation was added and gently pipetted. Cells were left on ice 
for 30 minutes incubation. Aliquots were then heat shocked at 42 °C for 45 
seconds and then immediately put back on ice for 2 minutes. Following the 
addition of 1 mL of SOC media at room temperature aliquots were then incubated 
at 37 °C for 60 minutes.  
The resulting cultures were then centrifuged at 4000xg on a bench top centrifuge 
for 30 seconds. The resulting pellet was then resuspended in 100 µL of SOC media 
and spread on pre-dried agar plates supplemented with the appropriate antibiotic 
for incubation at 37 °C overnight. 
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2.1.9.2 Glycerol Stocks 
Glycerol stocks for the long term storage of bacterial cells were made in the ratio 
of 1:1  with sterile 50% glycerol.  Glycerol stocks were stored at -80 °C. 
2.1.10 DNA Sequencing 
The correct integration of the PhoH2 gene insert into the expression plasmid was 
confirmed by Sequencing at Massey Genome Service, Massey University, 
Manawatu Campus. Plasmid samples were sent at 250 ng with 4 µM primers, up 
to a final volume of 20 µL with MilliQ water. 
2.2 Protein Expression and Purification 
2.2.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) Protein Analysis 
SDS-PAGE gels were comprised of a stacking gel (5 % acrylamide, pH 6.8) above a 
resolving gel layer (12 % acrylamide, pH 8). Acrylamide was added from a stock 
solution of 30 % acrylamide/bis (BioRad Laboratories, USA).  Gels were prepared 
in a Hoefer multiple gel casting system. Gels included 0.1 % (w/v) SDS, 0.05 % (w/v) 
ammonium persulfate (APS) and 0.05 % (v/v) Tetramethylethylenediamine 
(TEMED). 
Protein samples were mixed with 4x SDS loading buffer in a 3:1 ratio (4 % SDS, 20 
% glycerol, 250 mM Tris HCL pH 6.8, 10 % β-mercaptoethanol, 0.025 % (w/v) 
bromophenol blue) and heated for 5 minutes at 95 °C. Following loading onto SDS-
PAGE, gels were run at 70 V until the dye front had passed through the stacking 
layer, then at 150 V until through the resolving layer in 1x SDS-PAGE running buffer 
(25 mM Tris, 250 mM glycine, 0.1 % (w/v) SDS).  
2.2.3 Coomassie Blue Staining for Protein Gel electrophoresis 
Following electrophoresis, gels were individually incubated in 100 mL of 
Coomassie Blue stain (0.05 % Coomassie® R-250 in 25% isopropanol, 10% acetic 
acid). Gels in staining solution were micro waved for 30 seconds, then left on an 
orbital gel shaker at room temperature for 15 minutes. Coomassie stain was 
decanted, and the gel rinsed in MilliQ water before incubated in 100 mL destain 
solution (10% acetic acid) until desired background achieved. 
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2.2.4 Measurement of Protein concentration 
The concentration of protein was measured using the Nano-drop ND-1000 
spectrophotometer.  This measures absorbance at 280 nm and the protein 
concentration is calculated using the Beer-Lambert equation: A=ε.c.l 
A = absorbance at 280 nm  
ε = theoretical molar extinction coefficient (M-1 cm-1)  
c = concentration (M)  
l = pathlength (cm) 
The theoretical molar extinction coefficients (ε) were calculated by entering the 
amino acid sequence into the online programme ProtParam 
(http://web.expasy.org/protparam). 
2.2.5 Concentration of Protein Samples 
Fractions containing the Protein samples were pooled and spun in either 15 mL or 
2 mL Vivaspin concentrators (Sartoris AG, Germany) with a molecular weight cut 
off of 10 kDa.  
Concentrators were first equilibrated with 0.05 % (v/v) Tween-80 and suitable 
purification buffer. Pooled samples were added to the top reservoir and spun at 
3300 g at 4 °C in 20 minute intervals until the desired concentration or volume was 
reached. 
2.2.6 Small Scale Protein expression trial 
Small Scale 100 mL LB cultures of E. coli DH5α or BL21 containing the plasmid  for 
the desired protein expression were induced at OD600 = 0.4-0.6 by the addition of 
IPTG and grown overnight at 37 °C. Three mL of expression culture was spun down 
at 4000xg on a bench-top centrifuge for 1 minute.   
The supernatant was discarded, and the pellet resuspended in 250 µL lysis buffer, 
50 mM Tris pH 8.0, 200 mM NaCl and 20 mM Imidazole, unless otherwise stated. 
Following sonciation using an Ultra sonic processor XL 2020 (Misonix 
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incorporation, SA), the sample was centrifuged at 4000xg for 20 minutes at 4 °C.  
The supernatant was then loaded onto Ni2+ Sepharose beads pre-equilibrated with 
lysis buffer and incubated at room temperature for 15 minutes. Following light 
centrifugation, the supernatant was then discarded and the beads washed in 1 mL 
lysis buffer. Fifteen µL samples of the Whole Cell, Supernatant, Insoluble, Wash 
and resin were incubated at 95 °C for 5 Minutes in Qx4 quencher and then 
visualised on a 12 % SDS PAGE gel. 
2.2.7 Purification of His - Tagged proteins using IMAC/Nickel 
chromatography 
Large scale expression cultures (1 L) were lysed by sonication, and the resulting 
supernatant was filtered through 1.2, 0.45 and 0.2 µm Minisart filters (Sartorius 
AG, Germany). The Filtered supernatant was then loaded onto a 5 mL IMAC 
column (GE Sciences) following pre-equilibration with the appropriate lysis buffer 
in a 'drop-to-drop' method. The column was then connected to an AKTA Purifier™ 
FPLC system (GE Sciences). 
The 5 mL column was washed with 25 mL of lysis buffer at a flow rate of 1 mL/min 
to remove any excess unbound proteins. Bound proteins were removed and 
collected in 2 mL fractions by an increasing gradient of 0-50% elution buffer (Lysis 
buffer + 1 M Imidazole) over 50 mL at a flow rate of 1 mL/min. Fractions 
corresponding to the protein were analysed by SDS-PAGE (See section 2.2.1). 
2.2.8 Size Exclusion chromatography 
Following IMAC chromatography, further purification of the desired protein was 
achieved by Size exclusion chromatography.  IMAC fractions containing the 
desired protein were pooled, and concentrated (see section 2.2.5) until a final 
volume of 500 µL was reached.  A S200 10/300 column was connected to AKTA 
Purifier™ pre-equilibrated in size exclusion buffer (50 mM Tris pH 8.0, 200 mM 
NaCl, 1 mM EDTA and 1 mM DTT). Protein was then loaded into pre-equilibrated 
loop through 0.2 µm filter.  Following elution of the protein by size, fractions were 
collected in 0.5 mL volumes, and subsequently run on SDS-PAGE (See section 
2.2.1) to identify desired protein and their corresponding chromatograph peaks. 
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2.3 Protein ATPase Assays 
ATPase Assays were conducted to determine active populations of desired 
protein.  A standard curve was determined using concentrations of Potassium 
dihydrogen phosphate ranging from 0 - 50 mM, prepared in assay buffer (20 mM 
Hepes, pH 8.0, 20 mM NaCl) and 1 mM MgCl2. Control reactions were included 
that used an assay buffer that contained 2 mM EDTA. 
Pilot studies were performed to determine appropriate ATP and protein 
concentrations.  ATP ranged between 1 - 10 mM and protein concentration 
between 0.25 - 1 µM.   
Reactions of 100 µL were pre-equilibrated at 37 °C for 10 minutes before enzyme 
was added. The assay reaction was left for a further 10 minutes at 37 °C. Thirty µL 
of malachite green stop solution (1.5% ammonium molybdate, 0.18% Tween-80, 
0.1% malachite green, 14% sulfuric acid) was added to the reaction and held at 
room temperature for 10 minutes. Absorbance was read at 620 nm using 
Multiskan Go (Thermofisher Scientific).  
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3 Results 
3.1 Cloning, Expression and Purification of C. thermarum PhoH2 
3.1.1 Cloning and Expression 
To achieve the first objective of cloning, expressing and purifying PhoH2 protein, 
the PhoH2 gene from C. Thermarum was amplified and cloned into plasmids 
pET28b-PstI and pPROEX-HtB for protein over-expression in E. coli. 
Firstly, C. thermarum DNA was successfully extracted according to methods by 
Olsson (2002).  
Gradient PCR amplification from genomic DNA was conducted for optimum 
annealing temperature. Initial PCR used primers not containing restriction 
digesting sites, and resulting annealing temperature kept at 56 °C for subsequent 
amplifications. 
Many attempts were made to ensure successful cloning and thus expression of 
PhoH2 C. thermarum. Initially, PstI restriction endonuclease was used at the 
forward position, and HindIII restriction endonuclease at the reverse position for 
cloning into pET28b-PstI. Cloning was successful however DNA gels showed a 
smaller sized gene than expected following a post-cloning screen using the 
Cutsmart Double Digest system with PstI and HindIII (Figure 3.1). 
 
Figure 3.1: 1% agarose gels of the PhoH2 gene a) prior to restriction endonuclease 
digestion, and b) following restriction endonuclease digestion 
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Upon investigation to the cause of this smaller band it was discovered that phoH2 
from C. Thermarum contained a cutting sequence for PstI internally. Therefore, 
when the gene construct was digested by the Cutsmart double digest system prior 
to ligation and transformation the gene was also being cleaved internally. 
Thus, the forward restriction endonuclease was changed to XbaI, and the reverse 
kept as HindIII. The entire PhoH2 gene was successfully cloned into pET28b-PstI 
plasmid (Figure 3.2) and transformed into BL21 E.coli in preparation for protein 
expression, after confirmation of correct insertion by sequencing at the Massey 
Genome Service (MGS).  
 
Figure 3.2: PhoH2 insert following RE digest dropout to confirm the presence of 
PhoH2 in BL21 E.coli 
 
Small scale temperature expression trials were conducted post-induction with 
IPTG at 18 °C, 25 °C, 30 °C and 37 °C overnight alongside empty pET28b--PstI 
plasmids. No expression of the PhoH2 C. thermarum protein was observed with 
any of the expression temperatures (Figure 3.3). 
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Figure 3.3: 12 % SDS-PAGE gels showing the  small scale expression trials of PhoH2 
cloned into pET28b-PstI for expression in E. coli BL21 at 37 °C, 30 °C, 25 °C and 
18  °C. Controls containing empty pET28b-PstI were tested at 30 °C, 25 °C and 18 
°C in parallel. Expected band size 56 kDa not present in control or PhoH2 samples. 
Despite numerous attempts to obtain expression of PhoH2 protein, including 
Terrific Broth media no protein was observed. Revisiting the cloned construct 
sequence revealed the XbaI site in pET28b-PstI was downstream of the ribosome 
binding site (RBS). Thus, when the plasmid was digested with XbaI, and the PhoH2 
gene product ligated into pET28b-PstI, the RBS was removed, reducing the ability 
of E. coli BL21 to express the inserted PhoH2 protein despite the phoH2 gene 
sequence being correct. 
Upon this discovery, three new cloning constructs were designed to overcome this 
issue (Figure 3.4). Construct A used the same restriction endonucleases (XbaI and 
HindIII), and therefore the PhoH2 gene product used previously was directly 
inserted into the pPROEX-Htb plasmid for expression with an N-terminal His-tag in 
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either Dh5α or BL21 E. coli. While this was straight-forward to clone, and could be 
used to check for possible expression of PhoH2 protein, the C-terminus did not 
house a native stop codon, therefore an additional 8 amino acids were included at 
the C-terminus upon expression. Construct B removed these additional 8 amino 
acids by adding the native stop codon immediately following PhoH2. Construct C 
was more difficult to produce as 3 forward primers were used to re-introduce the 
RBS upstream of the PhoH2 start codon for re-cloning into pET28b-Pst for 
expression with a C-terminal His-tag in BL21 E. coli. 
 
Cloning Construct A 
Whilst the cloning of the PhoH2 gene into pPROEX-Htb plasmid (Construct A) was 
successful as determined by MGS sequencing, subsequent expression was 
problematic. Small scale expression trials initially showed a protein band of 
approximately the expected size (56 kDa) present in the whole cell and the resin 
samples for both trials conducted at 37 °C and 30 °C post-induction with IPTG, 
however it is notably lacking an enrichment of desired protein in the supernatant 
sample (Figure 3.5). 
PhoH2 C. thermarum 
PhoH2 C. thermarum 
PhoH2 C. thermarum 
N-terminus His-
Tag 141 Base Pairs 
N-terminal His-Tag 
141 Base Pairs 
C-terminus His-Tag 
42 Base pairs 
Downstream Stop Codon 
24 Base Pairs 
Insertion of RBS 
45 Base pairs 
a) 
b) 
c) 
Figure 3.1: Schematic diagram of the 3 cloning constructs 
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Figure 3.5: Small scale expression of PhoH2 in pPROEX-Htb plasmid from DH5α 
E. coli at 37 °C. Whole Cell, Supernatant, Insoluble, Wash 1, Resin. 
Given the enrichment on the Ni resin large scale (1 L) cultures in LB media were 
conducted at both 37 °C and 30 °C. Following lysis of the cells by sonciation, the 
soluble fraction was loaded onto a Nickel column for IMAC chromatography 
thereby separating the proteins based on their binding affinity to the Nickel resin 
(Figure 3.6). 
 
Figure 3.6: IMAC chromatography curve and corresponding 12 % SDS-PAGE of the 
fractions covering the main peaks as shown by the black line across the 
chromatography curve corresponding to fractions A1 – A12, grown at 37 °C. 
The main peak came off the Nickel column very early in the elution gradient 
(fractions A1-A3) as seen in Figure 3.6. The corresponding SDS-PAGE (Figure 3.6) 
shows two main proteins present in this primary peak, one at approximately 80 
kDa, another at approximately 48 kDa. There is also the presence of a slightly less 
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expressed protein, which was assumed to be PhoH2 at 56kDa. Fractions were also 
run of smaller secondary peaks at 13 mL (A5) and 27 mL (A12) respectively.  No 
protein bands corresponding to the expected size of PhoH2 were clearly observed, 
suggesting that PhoH2 may not be successfully expressed and purified similarly to 
what was seen in the small scale test (Figure 3.5). 
As these primary bands seen on the SDS-PAGE were not expected, a His-Tag stain 
was conducted on a SDS-PAGE with fractions taken from expression at both 37 °C 
and 30 °C following IMAC Ni chromatography. A control protein with a known His-
Tag from the Proteins and Microbes Lab was also included (Pfu) (Figure 3.7).  
 
Figure 3.7: His-tag stain 12% SDS-PAGE, followed by a standard Coomassie Stain. 
pFu protein was used as a control for size (47 kDa) and presence of His-tag. 
Fractions A1-A4 for both expression temperatures (37 °C and 30 °C) were loaded 
respectively. 
The His-tag stain showed that both the higher MW and lower MW bands and the 
band assumed to be PhoH2 contained a high percentage of histidine residues, 
indicating the likely presence of a His-tag and therefore the desired PhoH2 protein. 
Subsequent purification using size exclusion chromatography (Figure 3.8: Size 
Exclusion Chromatography Curve and Corresponding 12% SDS-PAGE a) 37 °C and 
b) 30 °C (Figure 3.8) separated these populations of protein for individual analysis 
by ATPase assays to confirm which population may or may not correspond to 
PhoH2. The elution volumes were entered into a calibration equation deduced for 
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this SE column and were calculated to correspond to the predicted MW of PhoH2 
if PhoH2 is oligomerising. 
The ATPase assays showed a consistent lack of activity (figures not shown), 
therefore the two protein populations were prepared for Mass 
Spectrophotometry which was carried out by commercial Lab MS3 Solutions. 
 
Figure 3.8: Size Exclusion Chromatography Curve and Corresponding 12% SDS-
PAGE a) 37 °C and b) 30 °C. 
The Mass Spectrophotometry results concluded that neither of these protein 
populations were PhoH2, but instead were identified as E.coli proteins Catalyse at 
84 kDa and Lac Repressor at 38.5 kDa. 
Cloning Construct B 
Construct B, in which there is an added native stop directly at the end of the PhoH2 
gene, was confirmed by MGS sequencing, and small scale expression trials were 
carried out in DH5α E.coli cells. 
A similar pattern to the first construct (A) was observed with this second construct 
(B). Small scale expression trials over a range of temperatures (37°C, 30 °C and 28 
°C) showed the presence of a PhoH2-sized band in the whole cell and resin samples 
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for all temperatures (Figure 3.9). However, large 1 L expression failed to produce 
visible PhoH2 band while again the E.coli Catalyse and Lac Repressor proteins were 
over-expressed. In the chromatography curves, a second minute peak was 
observed at approximately 60% Elution buffer (approximately 120 mM imidazole). 
Whilst very weak, initial SDS-PAGE shows this to be of consistent size to the 
expected size of PhoH2 (56 KDa). 
 
Figure 3.9: Small scale expression of PhoH2 in pPROEX-Htb plasmid in DH5α E.coli 
cells over 37 °C, 30 °C and 28 °C post-induction. The black boxes highlight the weak 
protein band of expected size present in Resin samples over all temperatures. Note 
there is no enrichment of PhoH2 in the 37 °C control (empty pPROEX-HtB). 
3.1.1.1 Purification 
Due to the above results being unsuccessful in yielding soluble protein multiple 
buffer conditions were explored. In order to carry out the prescribed biochemical 
characterisation assays, and eventually X-ray crystallography, the PhoH2 protein 
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is required to be as pure as possible, to attribute findings as a direct action of 
PhoH2 rather than other contaminant proteins. 
Typically, purification of recombinant proteins requires the desired protein to 
remain in solution following the lysis or rupture of the cell. The soluble protein is 
then separated according to biochemical property such as size, charge or binding 
ability by several chromatography techniques. 
Purification of the PhoH2 protein proved to be difficult, although the yield of 
PhoH2 appeared to be enriched in the whole cell. Upon lysis of the cell by 
sonication, PhoH2 was insoluble and was therefore retained in the pellet when 
centrifuged. An in depth buffer screen was conducted to determine the conditions 
in which PhoH2 remained in solution in order for downstream purification 
methods. 
Several small scale trials were conducted in order to determine the solubility of 
PhoH2 and therefore the ability for PhoH2 to bind to Nickel chromatography resin. 
Buffers were varied in pH, with constant NaCl and imidazole concentrations (Table 
3.1) with construct transformed into both DH5α (Figure 3.10) and BL21 E. coli cells 
(Figure 3.11). 
50 mM MES pH 6.0, 200 mM NaCl, 20 mM Imidazole 
50 mM HEPES pH 7.5, 200 mM NaCl, 20 mM Imidazole 
50 mM Tris pH 8.0, 200 mM NaCl, 20 mM Imidazole 
50 mM BisTris Propane pH 9.5, 200 mM NaCl, 20 mM Imidazole 
Table 3.1: Composition of purification buffers varying pH conditions. 
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Figure 3.10: SDS-PAGE gels of small scale expression trials screening increased salt 
concentrations and the addition of 10 % glycerol to lysis buffers on PhoH2 
expressed in DH5α E. coli cells. 
 
 
 
Figure 3.11: SDS-PAGE gels of small scale expression trials screening increased pH 
of lysis buffers on PhoH2 expressed in BL21 E. coli cells. 
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It appeared there was no significant improvement in the solubility of PhoH2 across 
the buffer pH range, however BisTris Propane pH 9.5 and Tris pH 8.0 buffers did 
show faint PhoH2 bands on the nickel resin, particularly with BL21 strain. Growth 
of the C. thermarum organism, appears in the literature to favour higher NaCl 
concentrations due to its halophilic properties, and with the purification of other 
C. thermarum proteins requiring glycerol to be included in the purification buffers 
[49]. A second buffer screen using Nickel pull down experiments investigated the 
solubility of PhoH2 in increased NaCl, both with and without 10% glycerol in 
attempt to increase the solubility and stability of PhoH2 upon cell lysis (Table 3.2). 
Results indicated enrichment of PhoH2 protein remaining in the insoluble pellet 
(Figure 3.12). 
50 mM Tris pH 8.0, 1.5 % NaCl, 20 mM Imidazole 
50 mM Tris pH 8.0, 0.5 M NaCl, 20 mM Imidazole 
50 mM Tris pH 8.0, 1.5 % NaCl, 20 mM Imidazole, 10 % Glycerol 
50 mM Tris pH 8.0, 0.5 M NaCl, 20 mM Imidazole, 10 % Glycerol 
Table 3.2: Composition of purification buffers varying Salt and glycerol conditions. 
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Figure 3.12: SDS-PAGE gels of small scale expression trials screening increased 
salt concentrations and the addition of 10 % glycerol to lysis buffers on PhoH2. 
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Due to the above attempts towards gaining soluble protein, consultation with Dr 
Emma Andrews and Prof. Vic Arcus regarding the previous refolding trials on the 
domains of PhoH2 from M. tuberculosis, and the time constraints for this thesis, 
refolding trials were not attempted. 
Cloning Construct C 
Construct C in which the PhoH2 gene is inserted into pET28b-PstI with primers 
which also add the RBS ahead of the PhoH2 gene was kindly cloned by Dr Emma 
Andrews and transformed into E.coli BL21 cells. Dr Andrews also carried out initial 
small scale expression trials in LB media with IPTG induction over a range of 
temperatures which resulted in little to no evident expression. 
This construct was not further pursued. Additional expression trials would be 
required to test for expression using alternate media, such as auto-expression, 
terrific broth and 2xYT media. 
The identification of alternative start sites 
Further inspection of C. thermarum TA2.A1 genome including the 300 bp region 
upstream of PhoH2 provided curious options. Initial searches investigated possible 
antitoxin binding partners similar to those which bind and stabilize PIN domain 
VapC toxins. Options presented here were discounted as suitable antitoxins due 
to: 
 Presence of a stop codon in the antitoxin sequence 
 Not a multiple of 3, therefore unable to translate into amino acids 
 Very short, only 30 aa long 
Further searches identified alternative starting sites for the PhoH2 gene which 
may have previously been overlooked as C. thermarum TA2. A1 has not been 
entirely annotated (the initial sequence for PhoH2 from C. thermarum was 
identified with a BLAST search using PhoH2 from M. tuberculosis as a reference 
sequence). A short 30aa sequence and 18aa sequence immediately upstream of 
PhoH2 surprisingly showed homology to sequences found in DEAD/H box helicase 
proteins. Due to this and fortunately as we have access to the TA2. A1 genomic 
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DNA, these 2 alternative start sites were investigated in the hope that the 
additional upstream sequences would stabilize and fold PhoH2 correctly, yielding 
soluble PhoH2 protein. 
3.1.1.2 PhoH2 + 30 amino acids  
This new construct consists of the original C. thermarum PhoH2 sequence with an 
additional 30 amino acids upstream which are natively found in the C. thermarum 
TA2.A1 genome (Figure 3.13). These 30 amino acids begin with a Methionine 
residue, which is recognised by E. coli as a translation start site.  
 
3.1.1.3 PhoH2 + 18 amino acids 
The second construct contains an additional 18 amino acid sequence upstream of 
PhoH2 (Figure 3.14). These 18 amino acids contain only the sequence identified in 
BLAST searches that has homology to DEAD/H box helicase proteins. 
 
 
New forward primers corresponding to the two alternative start sites were 
designed with an EcoRI restriction site and ordered from IDT technologies. EcoRI 
was used as it would be suitable for insertion into both pPROEX-Htb and pET28b-
PstI plasmids, therefore allowing studies with the His tag on either the N-terminus 
or C-terminus respectively. The reverse primers remained the same as previously 
used, for pPROEX-Htb this primer included the native stop codon and HindIII 
restriction site and for cloning into pET28b-PstI this excluded this stop codon but 
 
C. thermarum PhoH2 30 aa  
Helicase homology 
sequence 
 
Figure 3.14: Schematic diagram of 18-PhoH2 construct. 
Figure 3.13: Schematic diagram of 30-PhoH2 construct. 
C. thermarum PhoH2 18 aa 
Helicase 
homology 
sequence 
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included the HindIII restriction site. For the purpose of continuity, pPROEX-Htb 
plasmid was focused on initially while the pET28b-Htb-PstI plasmid was prepared 
for future use. 
Using HotFire Polymerase, an initial gradient annealing temperature PCR was 
performed with temperatures ranging from 50-60 °C. Both the 30 and 18 PhoH2 
constructs had good amplification across all temperatures, however 58 °C showed 
the cleanest product (Figure 3.15). Therefore 58 °C was chosen as the annealing 
temperature for subsequent PCRs. 
 
 
Following the correct cloning of the 30-PhoH2 insert into pPROEX-Htb, confirmed 
by MSG sequencing, once again, the pPROEX-Htb 30- PhoH2 was expressed in 
small scale 100 mL LB media, and underwent small scale expression trials in order 
to try to gain soluble protein for further biochemical characterisations. 
Temperatures following induction with IPTG were trialled at 28 °C, 30 °C and 37 °C. 
There appeared to be no observable difference in the solubility of the 30- PhoH2 
protein across the temperatures (Figure 3.16). There was also no difference in 
expression, therefore subsequent small scale expression trials in various buffers 
were carried out using cells which were grown and induced at 37 °C. 
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PhoH2 and 18-PhoH2 constructs respectively. 
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Subsequent lysis buffer screens across pH (Figure 3.17) and NaCl and glycerol 
(Figure 3.18) addition also shows the desired 30-PhoH2 protein remains insoluble. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: SDS-PAGE gels of small scale expression trials screening variable 
expression temperatures 37°C, 30°C and 28°C using lysis buffer 50 mM Tris pH 
8.0, 200 mM NaCl, 20 mM Imidazole in 30-PhoH2. 
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Figure 3.17: SDS-PAGE gels of small scale expression trials screening increased pH 
of lysis buffers in 30-PhoH2. 
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The insert for 18-PhoH2 were also cloned by gradient PCR (Figure 3.15), and 
successfully ligated into pPROEX-Htb plasmid and transformed into DH5α E. coli 
cells. The above small scale expression trials were also conducted on this construct 
(Figure 3.19, Figure 3.20, Figure 3.21). 
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Figure 3.18: SDS-PAGE gels of small scale expression trials screening increased salt 
concentrations and the addition of 10 % glycerol to lysis buffers in 30-PhoH2. 
Figure 3.19: SDS-PAGE gels of small scale expression trials screening variable 
expression temperatures 37°C, 30°C and 28°C using lysis buffer 50 mM Tris pH 
8.0, 200 mM NaCl, 20 mM Imidazole in 18-PhoH2. 
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Figure 3.20: SDS-PAGE gels of small scale expression trials screening increased pH 
of lysis buffers in 18-PhoH2. 
 
 
Additionally, work was carried out which aimed to clone the two alternative start 
sites into pET28b-PstI plasmid. Both 30-PhoH2 and 18-PhoH2 inserts were 
Figure 3.21: SDS-PAGE gels of small scale expression trials screening increased 
pH of lysis buffers in 18-PhoH2. 
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amplified from gDNA using HotFire Polymerase PCR successfully, the 30-PhoH2 
insert was then ligated into pET28b-PstI. 
While for this construct cloning was achieved, the 18-PhoH2 insert was more 
difficult to ligate into the same digested pET28b-PstI plasmid.  
18-PhoH2 amplification of the insert was repeated, and following the ligation and 
transformation into DH5α E. coli cells, there were minimal (5) colonies present. 
Colony PCR of these colonies using cloning primers showed a lack of 18-PhoH2 
insert. 
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Discussion 
Previous efforts into crystallising and structure solving of PhoH2 using X-ray 
crystallography have produced data to only modest resolution ~4 Å, but have been 
unsuccessful in determining the structure of PhoH2. Based on previous studies 
solving the structure of another large protein; ATP synthase, C. thermarum was 
predicted to be an advantageous candidate for steps towards solving the protein 
structure of PhoH2. The intended objectives for this study were to produce PhoH2 
protein crystals for X-ray crystallography and biochemical characterisation using 
previously worked up assays, the structure of which would then be used to model 
subsequent PhoH2 structures from other organisms. In order to achieve this goal, 
the protein PhoH2 needs to be expressed and remain soluble in large quantities, 
and purified away from other cellular proteins through multiple steps to gain 
soluble pure PhoH2. 
The above results describing the expression and purification trials undertaken of 
C. thermarum PhoH2 have not been able to produce conclusive conditions in 
which PhoH2 can be expressed and purified in a soluble form in preparation for 
downstream structural studies.  
Across all three possible start site constructs cloned into pPROEX-HtB for 
expression in DH5α E. coli; PhoH2, 18-PhoH2 and 30-PhoH2, numerous buffer 
conditions in which the induced cells containing the over-expressed C. thermarum 
PhoH2 were lysed by sonication (100 mL). These buffer conditions were chosen to 
replicate the in vivo environmental ionic cellular conditions in order to maintain 
the stability of the PhoH2 protein of interest [47], while other buffers were chosen 
directly from conditions used by other research groups using proteins also cloned 
from C. thermarum [48, 50].  
Lowering the temperature for protein expression following induction by the 
addition of IPTG failed to show any variation in the quantity of expressed protein, 
or any increase in solubility. The pH of the lysis buffer also did not improve the 
solubility. The addition of glycerol (5 - 10%) in the lysis buffer often increases the 
solubility of the protein, by decreasing the mobility of proteins and cellular debris 
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upon cellular lysis [51]. Addition of 10 % glycerol, in an attempt to stabilize the 
protein upon cell lysis was also unsuccessful, as was a range of salt concentrations 
in the lysis buffer. 
Increasing the salt concentration of the buffer is thought to screen out the 
strength of ionic interactions [52]. The salt concentration of the expression 
medium (LB) influences the aggregation of proteins in solution. The likelihood of 
protein aggregation differs between proteins due to the amino acids side chains 
present and exposed in a natively folded protein. Therefore if the presence of 
acidic residues within the protein of interest is considered high, the increase of 
salt in the lysis buffer is likely to increase the stability of the protein, preventing 
the aggregation and precipitation of the protein of interest. In C. thermarum 
PhoH2, contains approximately 13 % acidic residues (ProtParam), therefore 
buffers trialled contained a range of increased salt, ranging from 200 mM NaCl to 
500 mM NaCl, mimicking the halophilic environment C. thermarum tolerates. 
However, this did not appear to show any considerable improvement in the 
stability and thus the solubility of PhoH2. 
Solubility additives not explored in this study are primarily the use of detergents 
in the lysis buffer. Traditionally, detergents are used where the protein of interest 
is an integral membrane protein [53]. The addition of detergents, such as Triton X-
100 or deoxycholate up to 1%, are thought to increase the solubility of some 
proteins, by disrupting the cell membranes or releasing the proteins from 
aggregating into insoluble cellular debris. Given that the current studies into 
PhoH2 strongly suggest PhoH2 is not an integral membrane protein, but a 
cytoplasmic protein, the addition of a detergent to the lysis buffer is unlikely to 
result in significantly increased protein solubility. 
Trialling various media in which the cells containing the recombinant PhoH2 
protein is another option to improve the solubility upon lysis. Media conditions 
have the potential to induce cellular mechanisms such as an increased expression 
of chaperones which assist in the folding of the protein. Similarly, transforming the 
recombinant plasmid into Rosetta BL21 E.coli cells, or other strains which co-
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expresses Gro ES/EL chaperones may increase the solubility of recombinant 
proteins.  
Another factor in protein expression and purification is the presence of the linker 
region between the His-tag and the beginning of the PhoH2 protein when cloned 
into pPROEX. In pPROEX recombinant PhoH2, there are 47 amino acids between 
the N-terminal His-tag and the start codon of PhoH2. For the alternative start sites, 
30-PhoH2 and 18-PhoH2 the length between the His-tag and the start of PhoH2 is 
reduced to 30 amino acids due to the position of EcoRI cutting sequence in pPROEX 
compared to the cutting sequence of XbaI, however no increase in expression or 
solubility of the desired PhoH2 protein was observed. Regardless of the length of 
linker region, it is plausible this region interferes with native folding of the protein, 
preventing optimum stability and thus affecting the solubility of the protein upon 
cell lysis. This would have substantial effect on the stability particularly on the 
oligomerisation of multi-domain proteins, as PhoH2 is reported to be a hexamer 
[34]. Secondly, lysing the cells at a high temperature may maintain the solubility 
of PhoH2, while denaturing and precipitating the E.coli cellular proteins. 
Future studies following the above results may explore multiple options. 
Persistence with the current constructs using various expression media, cell lines 
and detergent containing media may be worthwhile. However, confirmation of 
cloning of PhoH2 into pET28b-PstI plasmid for expression with a C-terminal His-
tag removes the N-terminal linker between the His-tag and the beginning of the 
PhoH2 protein, may be a more successful option, given the previous studies by 
Andrews and Arcus (2015) showing soluble expression of PhoH2 with a C terminal 
His-tag with shorter linker region and adopted a hexamer conformation [34]. In 
addition to potentially gaining some degree of solubility, the lack of additional 
linker region would allow PhoH2 to be readily compared to PhoH2 from other 
organisms that have already been characterised, as was the original intention with 
the objectives of this study. Following the complete investigation into the pET28b-
PstI PhoH2 constructs if no improvement in the solubility of the protein is 
observed, investigations into studying a PhoH2 fusion protein from another viable 
thermophilic organism may be worthwhile.  
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Secondly, cloning, expressing and purifying the two domains (PIN and PhoH) 
individually in order to solve the separate structures and carry out basic 
biochemical characterisations could be a step towards solving the fusion PhoH2 
protein. This has partially been done where the PhoH domain taken from the 
PhoH2 fusion protein has been structurally solved and is currently the only 
published structure available for PhoH on the Protein data bank [34]. The 
corresponding PIN domain from the same organism does not have a structure 
available. Individually, these domains may be structurally solved, leading to 
information which may be applicable to the fusion PhoH2 protein. Considering this 
PhoH domain from C. glutamicum has already been characterised, it may be 
worthwhile perusing this organism for an initial PhoH2 structure. 
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